Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer

Condition:   HER2-positive Breast Cancer Interventions:   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Fulvestrant;   Drug: Capecitabine Sponsor:   Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials